safety sildenafil citrate review num double-blind placebo-controlled trials postmarketing safety database abstract aim review special safety topics sildenafil document tolerability num num mg doses age men erectile dysfunction ed methods data collated num double-blind placebo-controlled dbpc trials num men conducted manufacturer manufacturer postmarketing safety database num patients dbpc data stratified dose starting dose age num num years special safety topics included cardiovascular risk priapism non-arteritic anterior ischaemic optic neuropathy naion impaired renal hepatic function drug interactions i e nitrates cytochrome num inhibitors ed therapies blockers incorrect results sildenafil tolerated dose num num mg men ed aged num years aged num years analyses databases reveal causal link sildenafil cardiovascular events safety risks relating cardiovascular events priapism naion hearing loss drug interactions small number men moderate impairment renal function hepatic function treated sildenafil dbpc trials safety profile similar men impairment renal hepatic function overdose sildenafil rare ed population safety issues emerging trends adverse reactions identified conjunction overdose dependence abuse misuse conclusion collated review confirms generally good tolerability established safety profile sildenafil num num mg men ed reveals safety issues 
